Arthur He CFA, an analyst from H.C. Wainwright, maintained the Hold rating on LAVA Therapeutics (LVTX – Research Report). The associated price target remains the same with $1.50.
Arthur He CFA has given his Hold rating due to a combination of factors including LAVA Therapeutics’ ongoing strategic review and the advancement of their LAVA-1266 program. The company is currently focusing on evaluating strategic options to enhance shareholder value, following a significant workforce reduction. The progress of LAVA-1266, which targets CD123 for acute myeloid leukemia and myelodysplastic syndrome, is seen as a potential upside if it achieves significant clinical milestones.
Financially, LAVA Therapeutics reported better-than-expected license revenue for the fourth quarter of 2024, but still faces projected net losses for 2025. The company’s cash reserves are deemed sufficient to support operations into 2027, which provides some financial stability. However, the valuation and risks associated with clinical, regulatory, and commercial factors, among others, contribute to maintaining a Neutral rating with a price target of $1.50 per share.
According to TipRanks, He CFA is a 4-star analyst with an average return of 16.7% and a 42.86% success rate. He CFA covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, LAVA Therapeutics, and Solid Biosciences.